Table S3.
Treatment patterns for patients with advanced NSCLC, nonsquamous histology and EGFR/ALK-positive statusa
| Treatment regimen | EGFR/ALK positive |
|---|---|
| First-line therapy | (N=46) |
| Platinum combination | 4 (9) |
| Carboplatin, pemetrexed | 2 (4) |
| Bevacizumab, carboplatin, paclitaxel | 1 (2) |
| Carboplatin, paclitaxel | 1 (2) |
| Single agent | 1 (2) |
| Bevacizumab | 1 (2) |
| EGFR/ALK TKI | 41 (89) |
| Gefitinib | 38 (83) |
| Erlotinib | 1 (2) |
| Crizotinib | 2 (4) |
| Second-line therapy | n=30 |
| Platinum combination | 13 (43) |
| Carboplatin, paclitaxel | 5 (17) |
| Bevacizumab, carboplatin, pemetrexed | 4 (13) |
| Carboplatin, pemetrexed | 3 (10) |
| Bevacizumab, carboplatin, paclitaxel | 1 (3) |
| Single agent | 2 (7) |
| Pemetrexed | 2 (7) |
| EGFR/ALK TKI | 15 (50) |
| Erlotinib | 11 (37) |
| Gefitinib | 2 (7) |
| Afatinib | 2 (7) |
| Third-line therapy | n=15 |
| Platinum combination | 3 (20) |
| Carboplatin, pemetrexed | 2 (13) |
| Cisplatin, erlotinib, tegafur/gimeracil/oteracilb | 1 (7) |
| Nonplatinum combination | 2 (13) |
| Gefitinib, pemetrexed | 1 (7) |
| Gemcitabine, vinorelbine | 1 (7) |
| Single agent | 1 (7) |
| Docetaxel | 1 (7) |
| EGFR/ALK TKI | 9 (60) |
| Erlotinib | 9 (60) |
Notes: Data are n (%). Percentages may not be additive because of rounding.
a
The top 5 regimens for each category are presented.
b
Oral anticancer drug composed of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:1:0.4.
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.